Pharma News, 2026

UCB’s Bimzelx showed superiority over AbbVie’s Skyrizi in a Phase III psoriatic arthritis study, though analysts doubt a major impact on drug sales.

The MHRA has approved Sun Pharma's Leqselvi (deuruxolitinib) as a new treatment for adults with severe alopecia areata, showing strong hair regrowth results.

Iovance Biotherapeutics announces positive early data for its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas, showing a 50% ORR.

HeartWorks is developing a preclinical biomedical innovation hub in Wisconsin to accelerate cardiovascular solutions and support early-stage MedTech startups.

Redx Pharma receives FDA Fast Track Designation for RXC008, a novel pan-ROCK inhibitor for fibrostenotic Crohn’s disease. Phase 2 trials begin this year.

Indiana University researchers found that depleting fibrinogen, a liver clotting protein, slows pancreatic cancer growth and reduces liver metastasis.

Hoth Therapeutics announces positive female preclinical data showing HT-VA (GDNF) restores cholesterol and improves lipid metabolism in a MASLD model.

FDA expands approval for leucovorin to treat cerebral folate deficiency with FOLR1 variant, clarifying its use after prior hype as a broad autism treatment.

EMA proposes new draft guidelines to accelerate clinical trial approvals during public health emergencies, prioritizing robust data and participant safety.

Servier acquires Day One Biopharmaceuticals for $2.5bn, adding Ojemda (tovorafenib) for pediatric glioma to its growing rare oncology pipeline.

Amplia Therapeutics presented preclinical data showing its FAK inhibitor narmafotinib enhances kRAS inhibitors in mutated pancreatic and lung cancers.

Vinay Prasad leaves his role as FDA's CBER head after eight months. His departure marks another major leadership change amid ongoing agency controversies.